BioSpace News Archive

Lineage Cell Therapeutics, Inc. today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets.

Inhalon Biopharma today announced a new agreement with the University of Georgia to license a panel of Human Metapneumovirus (hMPV) antibodies.

Processa Pharmaceuticals, Inc. announces the formation of its Oncology Advisory Board featuring key opinion leaders from multiple nationally-recognized institutions.

Ligand Pharmaceuticals Incorporated announced that it has acquired Tolerance Therapeutics, Inc. for $20 million in cash.

Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.

Kyverna Therapeutics (“Kyverna”), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the signing of a multi-year research funding agreement with Charité - Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology to investigate the impact of B- and plasma cell-targeting therapies.

Molecular Neurobiology publication demonstrated that NLRP3 inflammasomes have an important role in the pathogenesis of multiple sclerosis (“MS”) based on significant decreases in neuronal damage and demyelination resulting from NLRP3 inhibition in a mouse model of MS.

CureVac N.V. today announced solid progress in its clinical vaccine development programs in COVID-19 and seasonal flu, conducted in collaboration with GSK.

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that management will participate in the following investor conferences in November 2023.